Medicilon swings to profit as CRO demand recovers
Medicilon turns profitable in H1 2026 Medicilon reported first-half net profit of 51.6 million yuan, reversing a year-ago loss, with revenue up 40.9% to 761 million yuan and cash flow up 80.5%. This confirms the company's own turnaround, directly supporting the stock price.
This is the single most important new fact: the company itself became profitable, validating the recovery story.
Global innovative drug R&D demand is recovering Medicilon and peer Innostar both said global demand for innovative drug research is recovering, with solid order backlogs and higher capacity use. This means more business and better pricing ahead, pushing the stock up.
It explains the underlying force behind the profit swing and is a fresh confirmation from the actual half-year reports.
Sector-wide CRO earnings surge lifts sentiment WuXi AppTec's first-half profit topped 10 billion yuan and peers like Joinn and BioMap forecast huge gains, triggering limit-up moves across CRO stocks. Medicilon rose over 13% on the coattails, as investors bet on the whole sector.
It shows the powerful sector momentum that is pulling Medicilon's stock price up alongside its own results.
Rising lab monkey prices boost CRO profits The price of cynomolgus monkeys, a key cost for some CROs, climbed to 178,000 yuan, helping drive big profit forecast increases for companies like Joinn and Medicilon. Higher prices can signal strong demand and support margins.
It is a specific new driver behind the profit upgrades that readers may not know about.